M Urabe — Page 9 | Search PubMed

PubMedDate not supplied

Antitumor effect of pyridoglutethimide, an aromatase inhibitor, on 7,12-dimethylbenz(a)anthracene-induced mammary tumors of rat.

The antitumor effects of pyridoglutethimide (PG; 3-ethyl-3-(4-pyridyl) piperidine -2, 6-dione), a new analogue of aminoglutethimide (AG), were examined in rats with DMBA-induced mammary tumors. On the day following ovariectomy, the DMBA-treated rats were divided into four groups. The rats in each group (n = 25) received testosterone (20 mg/kg/day) or testosterone (20 mg/kg/day) with PG or AG (50 mg/kg/day) daily 6 times per weeks for 4 weeks; tumor volume was measured once weekly. Mammary tumors were dramatically increased after the administration of testosterone. However, in the rats receiving PG or AG simultaneously with testosterone, the tumors were significantly reduced with decrease of serum estradiol levels. Thus PG may suppress the growth of estrogen-dependent mammary tumors.

9,10-Dimethyl-1,2-benzanthracene↗

PubMedDate not supplied

Immunohistochemical localisation of aromatase and its correlation with progesterone receptors in ovarian epithelial tumours.

Aromatase cytochrome P-450 was immunohistochemically localised exclusively in the cytoplasm of neoplastic cells of benign and malignant nonfunctional ovarian tumours, whilst (progesterone receptors (PR) and estrogen receptors) (ER) were localised exclusively inn the nuclei of neoplastic cells. Aromatase activity and PR were detected in 68% (17/25) and 32% of the malignant tumours and 82% (22/27) and 67% of the benign tumours, respectively. In postmenopausal tumours, the positivity for PR in malignant tumours was less frequent (p < 0.01) than that in benign tumours. The tumours in which both aromatase and PR were positive, were less frequent (p < 0.05) in malignant than in benign tumours. Aromatase activity was detected in 100% (8/8) of the PR-positive tumours but in only 68% (9/17) of the PR-negative tumours. With postmenopausal malignant tumours, there was a positive correlation between aromatase activity and PR level (r = 0.77, p < 0.001). However, there was no significant difference in the positivity of ER. The serum steroid levels did not correlate with the tumour levels of aromatase activity, PR or ER. These findings suggest that aromatase activity is correlated with PR in ovarian tumours of postmenopausal women. In addition to steroid receptor status, aromatase activity may be a useful factor in ovarian cancer.

Adult↗